Published online Aug 26, 2021. doi: 10.4330/wjc.v13.i8.243
Peer-review started: March 15, 2021
First decision: April 26, 2021
Revised: May 19, 2021
Accepted: July 26, 2021
Article in press: July 26, 2021
Published online: August 26, 2021
Core Tip: The new generation of drug-eluting stents have different properties such as reduced strut thickness allowing lower level of local stent thrombosis, which may be feasible with shortened dual antiplatelet therapy (DAPT). Only a small number of individual stents have been validated for reduced DAPT, such as 1 mo for the BioFreedom stainless steel biolimus-eluting stent and the Onyx Resolute cobalt-chromium zotarolimus-eluting stent but in only certain populations. Future trials will compare DAPT durations within the same stent. Future research should also examine risk stratification and the parameters for patients to benefit the most from shortened DAPT.